Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raph...
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT₁A somatodendritic autoreceptors in the dorsal raphe nucleus

EM Rock¹, D Bolognini², CL Limebeer¹, MG Cascio², S Anavi-Goffer², PJ Fletcher³, R Mechoulam⁴, RG Pertwee² and LA Parker¹

¹Department of Psychology and Neuroscience Graduate Program, University of Guelph, Guelph, ON, Canada, ²Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK, ³Centre for Addiction and Mental Health and Department of Psychology, University of Toronto, Toronto, ON, Canada, and ⁴Institute of Drug Research, Hebrew University Medical Faculty, Jerusalem, Israel

BACKGROUND AND PURPOSE
To evaluate the hypothesis that activation of somatodendritic 5-HT₁A autoreceptors in the dorsal raphe nucleus (DRN) produces the anti-emetic/anti-nausea effects of cannabidiol (CBD), a primary non-psychoactive cannabinoid found in cannabis.

EXPERIMENTAL APPROACH
The potential of systemic and intra-DRN administration of 5-HT₁A receptor antagonists, WAY100135 or WAY100635, to prevent the anti-emetic effect of CBD in shrews (Suncus murinus) and the anti-nausea-like effects of CBD (conditioned gaping) in rats were evaluated. Also, the ability of intra-DRN administration of CBD to produce anti-nausea-like effects (and reversal by systemic WAY100635) was assessed. In vitro studies evaluated the potential of CBD to directly target 5-HT₁A receptors and to modify the ability of the 5-HT₁A agonist, 8-OH-DPAT, to stimulate [³⁵S]GTP₆ binding in rat brainstem membranes.

KEY RESULTS
CBD suppressed nicotine-, lithium chloride (LiCl)- and cisplatin (20 mg·kg⁻¹, but not 40 mg·kg⁻¹)-induced vomiting in the S. murinus and LiCl-induced conditioned gaping in rats. Anti-emetic and anti-nausea-like effects of CBD were suppressed by WAY100135 and the latter by WAY100635. When administered to the DRN: (i) WAY100635 reversed anti-nausea-like effects of systemic CBD, and (ii) CBD suppressed nausea-like effects, an effect that was reversed by systemic WAY100635. CBD also displayed significant potency (in a bell-shaped dose–response curve) at enhancing the ability of 8-OH-DPAT to stimulate [³⁵S]GTP₆ binding in rat brainstem membranes. Systemically administered CBD and 8-OH-DPAT synergistically suppressed LiCl-induced conditioned gaping.

CONCLUSIONS AND IMPLICATIONS
These results suggest that CBD produced its anti-emetic/anti-nausea effects by indirect activation of the somatodendritic 5-HT₁A autoreceptors in the DRN.
**Introduction**

The cannabis plant has been used for centuries for the suppression of nausea and vomiting (for review, Russo, 2007). Recent research has revealed that among more than 80 cannabinoïd compounds found in marijuana, both the intoxicant, Δ⁹-tetrahydrocannabinol (Δ⁹-THC; Darmani, 2001; Van Sickle et al., 2001; Kwiatkowska et al., 2004) and the non-intoxicant, cannabidiol (CBD; Kwiatkowska et al., 2004; Parker et al., 2004), suppress vomiting in animal models. CBD acts in a biphasic manner, such that low doses suppress toxin-induced vomiting but high doses potentiate (Darmani et al., 2004) or have no effect (Darmani et al., 2007) on vomiting. Both Δ⁹-THC and CBD also suppress the development of malaise-induced conditioned gaping reactions (Grill and Norgren, 1978a,b) in rats, a model of rat nausea-like behaviour (see Parker and Limebeer, 2008 for review). These conditioned gaping reactions in rats are only produced by drugs that also produce emesis in species capable of vomiting and are specifically prevented by pretreatment with anti-emetic drugs, such as the 5-HT₃ receptor antagonist, ondansetron (Limebeer and Parker, 2003) in animal models. It is likely that the attenuation of nausea-like behaviour by low doses of the 5-HT₃ receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, a classical 5-HT₃ receptor agonist) reduce their firing rate, thereby reducing the release of 5-HT in terminal regions (Verge et al., 1985; Blier and de Montigny, 1987). CBD also reduces the volume of cerebral infarction in animal models of ischaemic injury (see Hampson et al., 1998). This neuroprotective effect of CBD is mediated by 5-HT₁₉ receptors because it is reversed by the 5-HT₁₉ receptor antagonist (S)-N-n-propyl-2-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropamide, WAY100135 (Hayakawa et al., 2004, 2007a,b; Mishima et al., 2005). Also, CBD-induced reversal of cognitive and motor function impairments in a mouse model of hepatic encephalopathy is prevented by a 5-HT₁₉ receptor antagonist (Magen et al., 2010). When injected into the dorso-lateral periaqueductal grey, the anxiolytic effects of CBD are prevented by pretreatment with WAY100135, but not by the CB₁ receptor antagonist/inverse agonist AM251 (Campos and Guimaraes, 2008). Most recently, CBD has been reported to produce an antidepressant-like action which is 5-HT₁A receptor mediated (Zanelati et al., 2010). It is only recently that the mechanism of action for CBD’s anti-emetic and anti-nausea effects has been evaluated (see Parker and Limebeer, 2008). Unlike Δ⁹-THC, which produces its effect on emetic behaviours by its action on the CB₁ receptor (Darmani, 2001; Van Sickle et al., 2001; Parker et al., 2003, 2004), CBD has a very low affinity for both CB₁ and CB₂ cannabinoid receptors (Pertwee, 2004, 2008; receptor nomenclature follows Alexander et al., 2011), it has recently been shown to display unexpectedly high potency in vitro as an antagonist of CB₂ agonists in mouse vas deferens (Pertwee et al., 2002) and brain (Thomas et al., 2007) tissues. Additionally, CBD displays inverse agonism at the human CB₁ receptor (Thomas et al., 2007). CBD has also been reported to enhance adenosine signalling by inhibiting its re-uptake; in vivo treatment with a low dose of CBD decreased TNF-α production in lipopolysaccharide-treated mice (anti-inflammatory effect), an effect that was reversed with an Α₂a adenosine receptor antagonist and abolished in Α₂a receptor knockout mice (Carrier et al., 2006). CBD also acts as an antioxidant, potentially preventing damage in neurological disorders such as cerebral ischaemia (Hampson et al., 1998). The anti-arthritic potential of CBD may be the result of diminished IFN-γ release from lymph node cells in CBD-treated mice; subsequent in vitro experiments found that CBD suppressed the collagen type II-specific proliferation of lymph node cells from arthritic mice (Malfait et al., 2000).

Russo et al. (2005) recently reported that at a rather high concentration of 16 μM, CBD can bind to and activate human 5-HT₁₉ receptors. Somatodendritic 5-HT₁₉ auto-receptors in the raphe nuclei regulate the rate of firing of raphe 5-hydroxytryptaminergic afferents, and low doses of the 5-HT₁₉ receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, a classical 5-HT₁₉ agonist) reduce their firing rate, thereby reducing the release of 5-HT in terminal regions (Verge et al., 1985; Blier and de Montigny, 1987). CBD also reduces the volume of cerebral infarction in animal models of ischaemic injury (see Hampson et al., 1998). This neuroprotective effect of CBD is mediated by 5-HT₁₉ receptors because it is reversed by the 5-HT₁₉ receptor antagonist (S)-N-n-propyl-2-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropamide, WAY100135 (Hayakawa et al., 2004, 2007a,b; Mishima et al., 2005). Also, CBD-induced reversal of cognitive and motor function impairments in a mouse model of hepatic encephalopathy is prevented by a 5-HT₁₉ receptor antagonist (Magen et al., 2010). When injected into the dorso-lateral periaqueductal grey, the anxiolytic effects of CBD are prevented by pretreatment with WAY100135, but not by the CB₁ receptor antagonist/inverse agonist AM251 (Campos and Guimaraes, 2008). Most recently, CBD has been reported to produce an antidepressant-like action which is 5-HT₁A receptor mediated (Zanelati et al., 2010). It is only recently that the mechanism of action for CBD’s anti-emetic and anti-nausea effects has been evaluated (see Parker and Limebeer, 2008). Unlike Δ⁹-THC, which produces its effect on emetic behaviours by its action on the CB₁ receptor (Darmani, 2001; Van Sickle et al., 2001; Parker et al., 2003, 2004), CBD has a very low affinity for the CB₁ receptors (Mechoulam and Hanus, 2002) and its anti-emetic effect is not reversed by pharmacological blockade of these receptors (Parker et al., 2004). Like CBD, low doses of 8-OH-DPAT attenuate vomiting (Lucot and Crampton, 1989; Okada et al., 1994; Wolff and Leander, 1994; Andrews et al., 1996; Gupta and Sharma, 2002; Javid and Naylor, 2006) and conditioned gaping (Limebeer and Parker, 2003) in animal models. It is likely that the attenuation of nausea-like behaviour by low doses of 8-OH-DPAT is the result of action at somatodendritic 5-HT₁₉ autoreceptors in the dorsal raphe nucleus (DRN) and median raphe nucleus (MRN) because selective serotonin lesions of these nuclei also attenuate the establishment of lithium chloride (LiCl)-induced conditioned gaping reactions (Limebeer et al., 2004). Data reported in the literature show
that 5-HT is able to displace fully [³H]8-OH-DPAT from specific binding sites both in rat cerebral cortex membranes (Carli et al., 1996) and in human 5-HT₁₆-expressing CHO cell membranes (Newman-Iancredi et al., 1998). These findings suggest that 5-HT and 8-OH-DPAT bind to the same 5-HT₁₆ receptor binding site.

Here, we provide evidence that systemic pretreatment with a 5-HT₁₆ receptor antagonist attenuated the anti-emetic and anti-nausea-like effects of CBD. Furthermore, when administered intracranially into the DRN, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate (WAY100635) attenuated the anti-nausea-like effects of systemic CBD in rats. When CBD was administered directly into the DRN, LiCl-induced conditioned gaping reactions were suppressed in rats, an effect that was reversed by systemic WAY100635. In vitro data also demonstrated that CBD augmented the effect of 8-OH-DPAT in rat brainstem tissues, and this effect was confirmed by a synergistic effect of combined subthreshold systemic doses of CBD and 8-OH-DPAT on LiCl-induced conditioned gaping in rats.

Materials and methods

Animals

All animal care and experimental procedures complied with the Canadian Council on Animal Care (CCAC) and the National Institutes of Health guidelines and were approved by the Institutional Animal Care Committee, which is accredited by the CCAC. Male (30–45 g) and female (20–37 g) Suncus murinus (house musk shrews) ranging from 40 days to 180 days of age were bred and raised at the University of Guelph colony. They were single-housed in cages in a colony room at an ambient temperature of 21°C on a 14/10 light/dark schedule (lights off at 2100 h) as described in Parker et al., 2009. Shrews were tested during their light cycle, between 0800 h and 1700 h. The shrews had previous emetic experience with the limitation of a minimum of 3 weeks recovery between treatments. Because of its toxicity, cisplatin was always administered as the final treatment and shrews were killed thereafter.

Naïve male Sprague-Dawley rats, weighing between 275 and 350 g on the day of conditioning, obtained from Charles River Laboratories (St Constant, Quebec, Canada), were used for assessment of anti-nausea-like behaviour. They were single-housed in shoebox cages in the colony room at an ambient temperature of 21°C with a 12/12 light/dark schedule (lights off at 0800 h) and maintained on ad libitum food and water.

Drugs and materials

In vivo experiments. When systemically administered, CBD was prepared (2.5 mg·mL⁻¹ or 0.5 mg·mL⁻¹) in a vehicle of ethanol/Cremaphor (Sigma, St Louis, MO, USA)/saline (1:1:18) and administered s.c. 8-OH-DPAT HBr (8-OH-DPAT; Sigma) was prepared in saline (0.05 mg·mL⁻¹ or 0.005 mg·mL⁻¹) and administered s.c. The 5-HT₁₆ receptor antagonist, WAY100135 (Sigma; 5 mg·mL⁻¹; Mishima et al., 2005), and the more selective 5-HT₁₆ receptor antagonist (Forster et al., 1995), WAY100635 (Sigma; 0.1 mg·mL⁻¹; Campos and Guimaraes, 2008), were prepared in saline and administered i.p. LiCl (Sigma) was prepared in a 0.15 M solution with sterile water and was administered i.p. at a volume of 60 mL·kg⁻¹ (390 mg·kg⁻¹) in shrews (see Parker et al., 2004) and 20 mL·kg⁻¹ (127.2 mg·kg⁻¹) in rats. Nicotine (Sigma) bitartrate salt was prepared as a 2.5 mg·mL⁻¹ solution (expressed as a salt) in saline and administered s.c. at a dose of 5 mg·kg⁻¹ (2 mL·kg⁻¹) (Parker et al., 2009). Cisplatin (Sigma) was prepared as a 1 mg·mL⁻¹ solution in saline and was administered i.p. at doses of 20 mg·kg⁻¹ (20 mL·kg⁻¹) and 40 mg·kg⁻¹ (40 mL·kg⁻¹). When administered intracranially into the DRN, WAY100635 was prepared in sterile saline at a concentration of 21 ng in 0.5 μL (Herges and Taylor, 1999) and intracranially microinjected at 0.5 μL·min⁻¹ for 1 min. Intracranial CBD was prepared in 45% 2-hydroxypropyl-β-cyclodextrin at 10 μg·μL⁻¹ and intracranially microinjected into the DRN at 1 μL·min⁻¹ for 1 min (based on Murillo-Rodriguez et al., 2008).

In vitro experiments. CBD and 8-OH-DPAT HBr were supplied by Tocris (Bristol, UK). WAY100635 and fatty acid-free BSA were supplied by Sigma-Aldrich (Poole, Dorset, UK). For the binding experiments, [³S]GTPγS (1250 Ci·mmol⁻¹) and [³H]8-OH-DPAT (187 Ci·mmol⁻¹) were obtained from PerkinElmer Life Sciences Inc (Boston, MA, USA), GTPγS and adenosine deaminase from Roche Diagnostic (Indianapolis, IN, USA) and GDP from Sigma-Aldrich.

In vivo procedures

Effect of systemic injections of 5-HT₁₆ receptor antagonists on CBD-induced suppression of nicotine- LiCl- and cisplatin-induced vomiting in shrews

The shrews were moved into the experimental room from the colony room and given four meal worms in an empty cage 15 min prior to receiving two pretreatment injections. The first pretreatment injection was 1 mL·kg⁻¹ of saline or WAY100135, followed 15 min later by an injection of vehicle (2 or 4 mL·kg⁻¹) or CBD [2 mL·kg⁻¹ (5 mg·kg⁻¹) or 4 mL·kg⁻¹ (10 mg·kg⁻¹), depending upon the emetic treatment]. Thirty minutes later, shrews were given an injection of nicotine (5 mg·kg⁻¹), LiCl (390 mg·kg⁻¹) or cisplatin (20 or 40 mg·kg⁻¹). All shrews were then individually placed immediately into the clear Plexiglas observation chamber (22.5 × 26 × 20 cm) that sat on a table with a clear glass top. A mirror beneath the chamber on a 45° angle facilitated viewing of the ventral surface of the shrew to observe vomiting episodes. The duration of the test was determined by the duration of onset/action of the emetic effect of the drug: nicotine (15 min), LiCl (45 min) or cisplatin (60 min). The frequency of vomiting episodes (expulsion of fluids from the stomach) was counted by an observer unaware of the experimental conditions. Additionally, to evaluate the potential of the pretreatment drugs to produce vomiting on their own, six groups (n = 8/group) of shrews were injected with saline (60 mL·kg⁻¹) following pretreatment with saline or WAY100135 (10 mg·kg⁻¹) and, 15 min later, with vehicle, 5 mg·kg⁻¹ or 10 mg·kg⁻¹ of CBD. They were observed for 60 min. None of the saline-treated shrews displayed vomiting following the
pretreatment injections; therefore, these groups were not included in the overall analyses.

The number of vomiting episodes elicited by nicotine or LiCl was entered into a one-way ANOVA, with subsequent Bonferroni post hoc comparison tests of significant main effects. The number of vomiting episodes elicited by either 20 or 40 mg·kg⁻¹ of cisplatin was entered into a 2 (saline or WAY100135) × 3 (vehicle, 5 mg·kg⁻¹ CBD or 10 mg·kg⁻¹ CBD) ANOVA. For all analyses, significance is defined as $P < 0.05$.

**Effect of systemic injections of 5-HT₁A receptor antagonists on CBD-induced suppression of LiCl-induced conditioned gaping in rats**

All rats were surgically implanted with an intra-oral cannula under isoflurane anaesthesia according to the procedures described by Limebeer et al. (2010). Following recovery from surgery (4 days), the rats received an adaptation trial in which they were placed in the taste reactivity (TR) chamber with their cannula attached to an infusion pump (KDS100, KD Scientific, Holliston, MA, USA) for fluid delivery. The TR chambers had the same specifications as the shrew observation chambers. Water was infused into their intra-oral cannula for 2 min at the rate of 1 mL·min⁻¹. On the day following the adaptation trial, the rats received a conditioning trial in which they received two pretreatment injections. The first pretreatment injection was 2 mL·kg⁻¹ of saline, 2 mL·kg⁻¹ of WAY100135 (10 mg·kg⁻¹) or 1 mL·kg⁻¹ of WAY100635 (0.1 mg·kg⁻¹). The second pretreatment injection given 15 min later was 2 mL·kg⁻¹ of vehicle or CBD (5 mg·kg⁻¹). The groups were as follows: saline-vehicle ($n = 13$), saline-CBD ($n = 9$), WAY100135-vehicle ($n = 8$), WAY100135-CBD ($n = 8$), WAY100635-vehicle ($n = 7$) and WAY100635-CBD ($n = 8$). Thirty minutes after the second pretreatment injection, the rats were individually placed in the chamber and intra-orally infused with 0.1% saccharin solution for 2 min at the rate of 1 mL·min⁻¹ while the orofacial responses were video recorded from a mirror at a 45° angle beneath the chambers, with the feed from the video camera (Sony DCR-HC48, Henry’s Cameras, Waterloo, ON, Canada) fire-wired into a computer. Immediately after the saccharin infusion, all rats were injected with 20 mL·kg⁻¹ of 0.15 M LiCl and returned to their home cage. The videotapes were later scored (at $1/2$ speed) by an observer unaware of the experimental conditions, using ‘The Observer’ (Noldus Information Technology Inc., Leesburg, VA, USA) for the gaping behaviour (large openings of the mouth and jaw, with lower incisors exposed). The mean number of gaping reactions elicited by the LiCl-paired saccharin solution was entered into a 3 (saline, WAY100135 or WAY100635) × 2 (vehicle or CBD) between-groups ANOVA, with subsequent planned comparison tests.

**Effect of intra-DRN WAY100635 and systemic CBD on conditioned gaping in rats**

In all experiments, each rat was also permanently implanted unilaterally, entering from either the left or right hemisphere (counterbalanced across rats) with an intracranial cannula directed towards the DRN. Rats were anaesthetized with isoflurane and stabilized in the flat skull position (according to Paxinos and Watson, 1986) in the stereotaxic frame. A stainless-steel guide cannula (22 G, 8 mm below pedestal; Plastics One, Roanoke, VA, USA) was implanted at an angle of 20° to the vertical so that the tip was located 2 mm dorsal to the DRN. Co-ordinates (relative to inter-aural zero) were: anterior-posterior (A-P) +1.2 mm, medial-lateral (M-L) 0.0 mm and ventral (V) +5.0 mm. The cannula was secured by three stainless steel screws and dental cement. At this time, the rat was given carprofen (0.1 mg·kg⁻¹ i.p.; Pfizer, Kirkland, QC, Canada) as an analgesic, and a stainless steel obturator was inserted in the cannula to maintain patency. All rats were then surgically implanted with an intra-oral cannula under isoflurane anaesthesia according to the procedures described by Limebeer et al. (2010). The rats had at least 5 days recovery before behavioural testing.

Verification of cannula placement into the DRN was determined by histological evaluation of tissue. Rats were injected with 85 mg·kg⁻¹ sodium pentobarbital (Euthansol, Intervet Canada Corp., Kirkland, QC, Canada) and were transcardially perfused with PBS (0.1 M) and 4% formalin. The brains were removed and stored at 4°C in 4% formalin solution for 24–48 h, after which they were placed in a 20% sucrose solution overnight at room temperature. The brains were then sliced in 60 μm sections using a CM1850 Leica cryostat (Leica Microsystems Inc., Concord, ON, Canada), and relevant sections were mounted on glass microscope slides. The tissue was later stained with cresyl violet and examined for accurate injector tip placement using a Leica MZ6 Stereomicroscope with a Leica DFC420 Digital Camera and Leica Application Suite software.

Following recovery from surgery, the rats received an adaptation trial in which they were placed in the TR chamber with their cannula attached to the infusion pump for fluid delivery. Water was infused into their intra-oral cannula for 2 min at the rate of 1 mL·min⁻¹. On the day following the adaptation trial, the rats received a conditioning trial in which they received two pretreatment injections. The first pretreatment injection, saline or WAY100635, was infused into the DRN at 0.5 μL·min⁻¹ for 1 min (with the injector tip protruding 2 mm below the tip of the cannula). The injector remained in place for an additional 1 min. Fifteen minutes later, the rats received a 2 mL·kg⁻¹ pretreatment injection of either vehicle or CBD (5 mg·kg⁻¹; s.c.). Thirty minutes later, the rats were individually placed in the chamber and intra-orally infused with 0.1% saccharin solution for 2 min at the rate of 1 mL·min⁻¹ while the orofacial responses were video recorded. Immediately after the saccharin infusion, all rats were injected with 20 mL·kg⁻¹ of 0.15 M LiCl and returned to their home cages. The final groups (with proper placement) were as follows: saline-vehicle ($n = 7$), saline-CBD ($n = 7$), WAY100635-vehicle ($n = 9$) and WAY100635-CBD ($n = 6$). Additionally, rats in group WAY100635-CBD ($n = 5$) with placements outside of the DRN were included in the analysis as a separate group. The mean number of gaping reactions elicited by the LiCl-paired saccharin solution was entered into a one-way ANOVA, with subsequent planned comparison tests.

**Effect of intra-DRN CBD and systemic WAY100635 on conditioned gaping in rats**

The rats were treated exactly as those receiving intra-DRN WAY100635, except as indicated. On the conditioning trial, they were injected i.p. with 1 mL·kg⁻¹ of saline or WAY100635.
(0.1 mg·kg⁻¹). Fifteen minutes later, vehicle or CBD (0.21 ng) was infused into the DRN at 0.5 μL·min⁻¹ for 1 min (with the injector tip protruding 2 mm below the tip of the cannula). The injector remained in place for one additional minute. Immediately after microinfusion the rats were infused in the TR chamber. The final groups (with proper placement) were as follows (DRN drug/systemic drug): vehicle-saline (n = 6), CBD-saline (n = 7), vehicle-WAY100635-vehicle (n = 6) and CBD-WAY100635-CBD (n = 5). The mean number of gaping reactions elicited by the LiCl-paired saccharin solution during the drug-free test was entered into a one-way ANOVA, with subsequent planned comparison tests.

**Effect of subthreshold doses of systemic injections of CBD and 8-OH-DPAT on LiCl-induced conditioned gaping in rats**

In Experiment A, the doses of CBD (2.5 mg·kg⁻¹) and 8-OH-DPAT (0.05 mg·kg⁻¹) initially tested were the half-optimal doses of each of these compounds previously demonstrated to interfere with conditioned gaping (Parker et al., 2002; Limebeer and Parker, 2003). However, at these doses, both CBD and 8-OH-DPAT each suppressed LiCl-induced conditioned gaping on their own; therefore, in Experiment B, lower (subthreshold) doses of each compound (0.5 mg·kg⁻¹ of CBD and 0.005 mg·kg⁻¹ 8-OH-DPAT) were then evaluated.

Twenty-four hours following adaptation, the rats received a conditioning trial in which they were administered a pre-treatment and a treatment injection. The pretreatment injection was 1 mL·kg⁻¹ of vehicle or CBD (2.5 mg·kg⁻¹ in Experiment A and 0.5 mg·kg⁻¹ in Experiment B), followed 15 min later by a treatment injection of 1 mL·kg⁻¹ of saline or 8-OH-DPAT (0.05 mg·kg⁻¹ in Experiment A or 0.005 mg·kg⁻¹ in Experiment B). This design resulted in the following groups for each of Experiments A and B: vehicle-saline (n = 7), CBD-8-OH-DPAT (n = 9), CBD-saline (n = 8) and vehicle-8-OH-DPAT (n = 8). Thirty minutes after the treatment injection, the rats were individually placed in the chamber and intra-orally infused with a 0.1% saccharin solution for 2 min at a rate of 1 mL·min⁻¹ while their orofacial and somatic responses were video recorded. Immediately following the saccharin infusion, the rats were injected with 20 mL·kg⁻¹ of 0.15 M LiCl and returned to their home cages. Ninety-six hours following the conditioning trial, the rats individually received a single drug-free test trial in which they were returned to the chamber and intra-orally infused with the 0.1% saccharin solution for 2 min (1 mL·min⁻¹) while their orofacial and somatic responses were video recorded. For each of Experiment A and B, the mean number of gaping reactions during the test trial was entered into a one-way ANOVA, with subsequent planned comparison tests.

**In vitro procedures**

**Preparation of cell membranes from rat brainstem**

Rat brainstem tissues were homogenized in ice-cold Choi lysis buffer (Tris–HCl 20 mM, sucrose 0.32 M, EDTA 0.2 mM, EGTA 0.5 mM, pH 7.5) containing Roche® protease inhibitor cocktail (1:40 v/v; Roche Diagnostics, Mannheim, Germany) and phenylmethylsulphonyl fluoride (1 mM). The homogenate was centrifuged at 13 500×g for 15 min, and the resulting pellet was kept in −80°C for at least 2 h. The pellet was then resuspended in TME buffer (50 mM Tris–HCl, EDTA 1.0 mM; MgCl₂ 3.0 mM; pH 7.4), homogenized and stored at −80°C.

**Radioligand displacement assay**

The assays were carried out with [³H]-8-OH-DPAT and Tris-binding buffer (50 mM Tris–HCl, 50 mM Tris–base, 0.1% BSA; pH 7.4), total assay volume 500 μL, using the filtration procedure described previously by Ross et al. (1999). Binding was initiated by the addition of rat brainstem membranes (500 μg protein per well). All assays were performed at 37°C for 60 min before termination by addition of ice-cold Tris-binding buffer and vacuum filtration using a 24-well sampling manifold (Brandel Cell Harvester; Brandel Inc., Gaithersburg, MD, USA) and Brandel GF/B filters that had been soaked in wash buffer at 4°C for at least 24 h. Each reaction well was washed six times with a 1.2 mL aliquot of Tris-binding buffer. The filters were oven-dried for 60 min and then placed in 5 mL of scintillation fluid (Ultima Gold XR, PerkinElmer). Radioactivity was quantified by liquid scintillation spectrometry. Specific binding was defined as the difference between the binding that occurred in the presence and absence of 1 μM unlabelled 8-OH-DPAT. The concentration of [³H]-8-OH-DPAT used in our displacement assays was 0.7 nM. The compounds under investigation were stored at −20°C as stock solutions of 10 mM in DMSO, the vehicle concentration in all assay wells being 0.1% DMSO.

**[³S]GTPγS binding assay**

The assays were carried out with GTPγS binding buffer (50 mM Tris–HCl, 100 mM NaCl, 3 mM MgCl₂, 0.2 mM EGTA and 0.1% BSA fatty acid free; pH 7.4) in the presence of [³S]GTPγS and GDP, in a final volume of 500 μL. Binding was initiated by the addition of [³S]GTPγS to the wells. Non-specific binding was measured in the presence of 30 μM GTPγS. Rat brainstem membranes were pre-incubated for 30 min at 30°C with 0.5 U·mL⁻¹ adenosine deaminase to remove endogenous adenosine. The drugs were incubated in the assay for 60 min at 30°C. The reaction was terminated by a rapid vacuum filtration method using Tris-binding buffer, and the radioactivity was quantified by liquid scintillation spectrometry. In all the [³S]GTPγS-binding assays, we used 0.1 nM [³S]GTPγS, 30 μM GDP and a protein concentration of 100 μg per well.

**Dissociation kinetics**

Dissociation kinetic assays were performed with the 5-HT₁₆ receptor agonist [³H]-8-OH-DPAT (0.7 nM) and Tris-binding buffer, total assay volume 500 μL. We used the ‘isotopic dilution’ method to measure the dissociation rate constant for [³H]-8-OH-DPAT from brainstem membranes (Christopoulos, 2000; Price et al., 2005). [³H]-8-OH-DPAT (0.7 nM) was incubated with rat brainstem membranes (500 μg protein per well) for 60 min at 25°C. Dissociation was initiated by the addition of 1 μM unlabelled ligand in the presence and absence of test compounds. Dissociation times of 0.5 to 120 min at 25°C were used. To determine the non-specific binding, experiments were also performed in the presence of a 1 μM concentration of the unlabelled ligand. Binding was
terminated by addition of ice-cold wash buffer (50 mM Tris–HCl, 50 mM Tris–base and 0.1% BSA) followed by vacuum filtration.

**Analysis of in vitro data**
Values have been expressed as means and variability as SEM or as 95% confidence limits. The concentrations of the compounds under investigation that produced a 50% displacement of radioligand from specific binding sites (EC<sub>50</sub> values) were calculated using GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA) and the corresponding K<sub>i</sub> values were calculated using the equation of Cheng and Prusoff (1973). Values for EC<sub>50</sub> maximal effect (E<sub>max</sub>) and SEM or 95% confidence limits of these values have been calculated by non-linear regression analysis using the equation for a sigmoid concentration–response curve (GraphPad Prism). The dissociation rate constant for [<sup>3</sup>H]8-OH-DPAT was calculated using a one-phase exponential decay equation (GraphPad Prism).

**Results**

**CBD-induced suppression of toxin-induced vomiting in shrews was reversed by pretreatment with 5-HT<sub>1A</sub> receptor antagonist**
CBD suppressed nicotine- and LiCl-induced vomiting in <i>S. murinus</i>, effects which were reversed by pretreatment with the 5-HT<sub>1A</sub> receptor antagonist WAY100135. Figure 1 shows the mean number of vomiting episodes elicited by nicotine (top half) and LiCl (bottom half) for each pretreatment group. The pretreatment group effect was significant for both the nicotine-treated shrews, F (3, 36) = 5.2, P < 0.01, and the LiCl-treated shrews, F (3, 50) = 5.6, P < 0.01. In each experiment, Group saline-CBD displayed significantly less vomiting than any other group (P < 0.05), which did not differ among themselves.

CBD also suppressed vomiting produced by 20 mg·kg<sup>−1</sup> of cisplatin, but not 40 mg·kg<sup>−1</sup> of cisplatin, with the former effect prevented by pretreatment with WAY100135. Figure 2 presents the mean number of vomiting episodes elicited by 20 mg·kg<sup>−1</sup> of cisplatin (top panels A) and 40 mg·kg<sup>−1</sup> cisplatin (bottom panels B) displayed by the shrews pretreated with saline (left-hand sections) or WAY100135 (right-hand sections) prior to an injection of vehicle, 5 mg·kg<sup>−1</sup> CBD or 10 mg·kg<sup>−1</sup> CBD. Among shrews administered 20 mg·kg<sup>−1</sup> cisplatin, but not 40 mg·kg<sup>−1</sup>, the 3 x 2 ANOVA revealed a significant interaction, F (2, 47) = 4.3, P < 0.05. For the group treated with 20 mg·kg<sup>−1</sup> cisplatin, among the saline-pretreated groups but not the WAY100135 pretreated groups, both groups pretreated with CBD (5 or 10 mg·kg<sup>−1</sup>) displayed fewer vomiting episodes (P < 0.05) than the vehicle-pretreated group. CBD did not interfere with vomiting produced by the higher dose of cisplatin (40 mg·kg<sup>−1</sup>). Systemic CBD-induced suppression of LiCl-induced conditioned gaping in rats was reversed by systemic pretreatment with 5-HT<sub>1A</sub> receptor antagonists
Systemic administration of the 5-HT<sub>1A</sub> receptor antagonists, WAY100135 and WAY100635, prevented the anti-nausea-like effect of CBD in rats, just as WAY100135 prevented the anti-emetic effects of CBD in shrews. As seen in Figure 3, the 2 x 3 ANOVA revealed a significant interaction, F (2, 47) = 3.4, P < 0.05; only rats that were pretreated with saline-CBD displayed a suppression of LiCl-induced conditioned gaping reactions during the drug-free test (P < 0.05). Groups pretreated with either antagonist before CBD did not display suppressed conditioned gaping reactions.

**Intra-DRN WAY100635 reversed the suppressive effect of systemic CBD on conditioned gaping in rats**
The accurate injector tip placements (circles) are presented in Figure 4A. The tips of the injectors were located in the DRN.
between 2.04 and 0.84 mm anterior to the inter-aural line for a total of 29 rats. A total of 20 rats had placements outside the DRN. The rats in group WAY-CBD with inaccurate placements (triangles) were included in the analysis as a separate group (WAY-CBD-OUT; \( n = 5 \)) for comparison with those receiving the antagonist in the DRN. Figure 4B presents a representative photomicrograph of the tip/track of the injector in the DRN.

When administered intracranially to the DRN, the 5-HT\(_{1A}\) receptor antagonist WAY100635 prevented the suppression of LiCl-induced gaping by CBD. As seen in Figure 5, there was a significant effect of pretreatment group, \( F(4, 28) = 4.4; Groups \) saline-CBD and WAY-CBD-OUT displayed fewer gaping reactions than all other groups (\( P < 0.05 \)).

<table>
<thead>
<tr>
<th>Pretreatment Group</th>
<th>Mean Number of Gapes</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEH (n=6)</td>
<td>15</td>
</tr>
<tr>
<td>5 mg·kg(^{-1}) CBD (n=5)</td>
<td>10</td>
</tr>
<tr>
<td>10 mg·kg(^{-1}) CBD (n=6)</td>
<td>5</td>
</tr>
</tbody>
</table>

**Figure 3**

Mean (±SEM) number of gapes elicited by LiCl-paired saccharin solution during the drug-free test trial. During conditioning, rats were pretreated with systemic saline (SAL), WAY100135 (10 mg·kg\(^{-1}\), i.p.) or WAY100635 (0.1 mg·kg\(^{-1}\), i.p.) 15 min prior to systemic vehicle (VEH) or CBD (5 mg·kg\(^{-1}\), s.c.). *\( P < 0.05 \), significant difference.

**Intra-DRN administration of CBD-induced suppression of LiCl-induced conditioned gaping, reversal by systemic administration of 5-HT\(_{1A}\) antagonist**

The injector tip placements (circles) are presented in Figure 6A. The tips of the injectors were located in the DRN between 2.04 and 0.84 mm anterior to the inter-aural line for a total of 24 rats. Only one rat in the CBD-saline group had his guide cannula placed outside of the DRN and this rat did not show the CBD-induced suppression of gaping but was not included in the analysis. Figure 5B presents a representative photomicrograph of the tip/track of the injector in the DRN.

When administered intracranially to the DRN, CBD suppressed LiCl-induced gaping and this effect was blocked by systemic administration of the 5-HT\(_{1A}\) receptor antagonist WAY100635. As seen in Figure 7, there was a significant effect of pretreatment group, \( F(3,20) = 11.0, P < 0.001; Group \) CBD-saline displayed fewer gaping reactions than all other groups (\( P < 0.001 \)).

**CBD enhanced the ability of a 5-HT\(_{1A}\) receptor agonist to stimulate \([^{35}S]GTP\gamma S\) binding to rat brainstem membranes**

There is already evidence that CBD, albeit at the rather high concentration of 16 \( \mu M \), can directly bind to and activate human 5-HT\(_{1A}\) receptors that have been transfected into Chinese hamster ovary cells (Russo et al., 2005). However, the ability of lower concentrations of this cannabinoid to activate 5-HT\(_{1A}\) receptors in vitro when they are expressed naturally at physiological levels in rat brainstem membranes has not been investigated before. Accordingly, we sought for evidence that CBD can directly target 5-HT\(_{1A}\) receptors in rat brainstem when administered in vitro at concentrations ranging from 1 nM to 10 \( \mu M \).

First, we compared the abilities of CBD and the 5-HT\(_{1A}\) receptor-selective agonist, 8-OH-DPAT, to displace...
from specific binding sites on rat brainstem membranes. These experiments showed that at concentrations of up to 10 μM, CBD does not share the ability of 8-OH-DPAT to induce such displacement (Figure 8). Since 5-HT1A receptors signal through Gi/o proteins (Alexander et al., 2008), we also compared the abilities of 8-OH-DPAT and CBD to stimulate [35S]GTPγS binding to rat brainstem membranes in a concentration-related manner. We found that 8-OH-DPAT can indeed induce such stimulation and, also, that this effect could be potently antagonized by the 5-HT1A receptor-selective antagonist, WAY100635 (Figure 9). In contrast, no detectable stimulation was observed in response to any of the concentrations of CBD used (Figure 9). We therefore decided to investigate whether the stimulatory effect of 8-OH-DPAT on [35S]GTPγS binding could be enhanced by CBD. This we did to explore the possibility that 5-HT1A receptor antagonists reduce CBD-induced anti-nausea like-effects because CBD augments activation of 5-HT1A receptors in the brainstem by endogenously released 5-HT. As shown in Figure 10, we found that at 100 nM, CBD produced an upward shift in the log concentration response curve of 8-OH-DPAT that resulted in a statistically significant increase in the $E_{\text{max}}$ but not the $EC_{50}$ of this 5-HT1A receptor-selective agonist. However, CBD did not increase the $E_{\text{max}}$ of 8-OH-DPAT at 1, 10 or 31.6 nM or at 1 μM (Figure 10). We also found that 100 nM CBD caused [35S]GTPγS binding to rise significantly above the basal level (0) in the presence of 10$^{-14}$ and 10$^{-12}$ M 8-OH-DPAT, but not in the presence of 10$^{-16}$ M 8-OH-DPAT ($P < 0.05$; 1-sample t-test; $n = 7$). The mean values for percent stimulation of [35S]GTPγS binding by 100 nM CBD in the presence of 10$^{-16}$, 10$^{-14}$ and 10$^{-12}$ M 8-OH-DPAT were 3.3 ± 1.5%, 9.5 ± 1.8% and 12.2 ± 2.7%, respectively.

There is good evidence that some compounds that enhance the ability of agonists to activate certain G protein-coupled receptors do so by targeting allosteric sites on these receptors in a manner that slows the rate at which these agonists dissociate from their receptors (Christopoulos and Kenakin, 2002). Accordingly, because there is also evidence for the presence of an allosteric site on the 5-HT1A receptor (Barrondo and Salles, 2009), we investigated the ability of an 8-OH-DPAT-potentiating concentration of CBD (100 nM) to alter the rate at which [3H]8-OH-DPAT dissociated from specific binding sites in rat brainstem membranes. Our experiments showed that the mean dissociation rates of [3H]8-OH-DPAT in the presence of vehicle or of 100 nM CBD
were not significantly different. More specifically, these values, with their 95% confidence limits shown in parentheses, were 10.0 min (7.1 and 17.0) and 6.0 min (4.4 and 9.4), respectively ($n = 6$).

**CBD and 8-OH-DPAT acted synergistically to suppress LiCl-induced conditioned gaping in rats**

Because the *in vitro* data suggested that at 100 nM CBD potentiated the stimulation of $[^{35}S]GTP^\gamma S$ binding of 8-OH-DPAT in rat brainstem tissue, we next evaluated the potential of subthreshold doses of CBD to potentiate the anti-nausea-like effect of 8-OH-DPAT. When given at half the optimal dose during conditioning (Parker *et al*., 2002; Limebeer and Parker, 2003), both pretreatments suppressed LiCl-induced conditioned gaping reactions. The upper half of Figure 11 presents the mean number of conditioned gaping reactions elicited on the test trial for each group in Experiment A. There was a significant effect of group $F (3, 28) = 3.9, P < 0.025$. All groups displayed fewer gaping reactions than vehicle-saline, with no other significant group differences.

When the doses of CBD and 8-OH-DPAT were reduced such that each was ineffective in suppressing LiCl-induced conditioned gaping alone, the combined effect of these two doses interfered with the establishment of conditioned gaping reactions. The lower half of Figure 11 presents the mean number of conditioned gaping reactions elicited on the

---

**Figure 7**

Mean (±SEM) number of gapes elicited by LiCl-paired saccharin solution during the drug-free test. During conditioning, rats were pretreated with systemic saline (SAL) or WAY100635 (0.1 mg·kg$^{-1}$, i.p.) 15 min before intracranially administered vehicle (VEH) or CBD (10 µg) into the DRN. *P < 0.001, significant difference.
test trial for each group in Experiment B. There was a significant pretreatment effect of group \( F(3,26) = 5.9, P < 0.01 \). As is apparent, group 0.5 CBD-0.005 8-OH-DPAT gaped significantly (\( P < 0.05 \)) less than all other groups, with no other significant group differences.

**Discussion**

Consistent with previous work, a low dose of systemically administered CBD suppressed nicotine-, LiCl- and cisplatin-induced vomiting in \( S. \) *murinus* (Kwiatkowska *et al*., 2004; Parker *et al*., 2004) and LiCl-induced conditioned gaping in rats (Parker *et al*., 2002). The CBD-induced suppression of vomiting and conditioned gaping was attenuated by pretreatment with 5-HT1A receptor antagonists (WAY100135 and WAY100635). Most interestingly, when WAY100635 was infused directly into the DRN, but not in adjacent structures, the CBD-induced suppression of gaping was also attenuated. The effectiveness of CBD itself to suppress nausea-like behaviours when administered to the DRN and the reversal of this effect by systemic administration of WAY100635 provide additional evidence that the anti-nausea-like action of CBD is produced by its action on 5-HT1A receptors in the DRN. As the DRN is a site of the somatodendritic 5-HT1A autoreceptors, stimulation of which reduces the firing rate of 5-HT afferents to terminal regions (Verge *et al*., 1985; Sotelo *et al*., 1990), these results suggest that CBD may exert its anti-nausea-like effects by reducing the firing rate of 5-HT afferents to terminal forebrain regions. It is likely that these effects were mediated by CBD-induced augmentation of the action of endogenous 5-HT on the 5-HT1A receptor because CBD enhanced the action of 8-OH-DPAT in both *in vitro* (% stimulation of \([35S]\text{GTP} \gamma \text{S} \) binding above basal) and *in vivo* (conditioned gaping) experiments, but did not have a direct agonist action on the 5-HT1A receptor in the brainstem preparation.

Although rats (unlike shrews) are not capable of vomiting, they do exhibit conditioned gaping reactions in response to oral infusion of a flavour that has previously been paired with illness (Grill and Norgren, 1978a,b). These gaping reactions are only produced by drugs that induce vomiting in other emetic species, such as shrews (Parker, 2003; Parker *et al*., 2008). In fact, Travers and Norgren (1986) suggest that the muscular movements involved in the gaping response mimic those seen in species capable of vomiting. Previously, we found that the anti-emetic drug, ondansetron (a 5-HT3 receptor antagonist), suppressed LiCl-induced conditioned gaping in rats, presumably by reducing the nausea produced by the emetic treatment (Limebeer and Parker, 2000). Consistent with the findings of the present study, the 5-HT1A receptor agonist, 8-OH-DPAT, also interfered with LiCl- (Limebeer *et al*., 2004) and fluoxetine-induced gaping in rats (Limebeer *et al*., 2009) as well as toxin-induced vomiting in other species (see: Lucot and Crampton, 1989; Andrews *et al*., 1996; Javid and Naylor, 2006). Of most relevance, depletion of forebrain 5-HT induced by 5,7-dihydroxytryptamine (5,7-DHT) lesions of the MRN and the DRN also prevented the LiCl-induced conditioned gaping reactions (Limebeer *et al*., 2004) that rely on an intact forebrain (Grill and Norgren, 1978a). Forebrain 5-HT may therefore be critical for the establishment of these nausea-like behaviours in rats.

The therapeutic effects of CBD on ischaemic injury (Hayakawa *et al*., 2004, 2007a; Mishima *et al*., 2005), hepatic encephalopathy (Magen *et al*., 2010), anxiety (Campos and Guimaraes, 2008; Gomes *et al*., 2011) and depression (Zanelati *et al*., 2010) are each attenuated by pretreatment with 5-HT1A antagonists. Here, we report that the CBD-induced suppression of vomiting in shrews and conditioned
gaping in rats is also reversed by 5-HT1A antagonists. Furthermore, the site of action of the anti-nausea-like effect of CBD appears to be the somatodendritic 5-HT1A autoreceptors in the DRN, which have been reported to reduce the firing rate of 5-HT afferents to terminal forebrain regions (Verge et al., 1985; Sotelo et al., 1990). These results suggest that CBD may exert its anti-nausea-like effects by reducing the release of 5-HT in terminal forebrain regions (as yet to be identified).

Because we found that CBD enhances the ability of the 5-HT1A receptor-selective agonist, 8-OH-DPAT, to stimulate [35S]GTP\(\gamma\)S binding to rat brainstem membranes with significant potency, CBD may suppress LiCl-induced conditioned gaping in rats by augmenting activation of 5-HT1A receptors in the brainstem produced by endogenously released 5-HT. Indeed, this hypothesis was supported by the synergistic effects of subthreshold doses of 8-OH-DPAT and CBD on suppression of

**Figure 10**

Effect of 8-OH-DPAT on [35S]GTP\(\gamma\)S binding to rat brainstem membranes in the presence of DMSO (VEH) or CBD. Mean \(E_{\text{max}}\) values for 8-OH-DPAT in panels A, B, C, D and E with 95% confidence limits shown in parentheses were 35.1% (26.6 and 43.5%; \(n = 8\)), 34.8% (30.3 and 39.3%; \(n = 8\)), 44.3% (33.4 and 55.1%; \(n = 6\)), 32.4% (22.8 and 41.9%; \(n = 10\)) and 32.0% (22.9 and 41.1%; \(n = 9\)), respectively, in the presence of vehicle and 34.0% (22.2 and 45.9%; \(n = 8\)), 43.3% (35.5 and 51.0%; \(n = 6\)), 51.3% (39.3 and 63.3%; \(n = 10\)) and 28.4% (18.5 and 38.3%; \(n = 9\)), respectively, in the presence of 1nM, 10 nM, 31.6 nM, 100 nM or 1 \(\mu\)M CBD. Corresponding mean EC\(50\) values for 8-OH-DPAT were 11.2 nM (1.9 and 66.7 nM), 22.0 nM (9.5 and 50.9 nM), 37.3 nM (8.1 and 173 nM), 12.7 nM (1.2 and 139 nM) and 37.4 nM (6.3 and 222 nM), respectively, in the presence of vehicle and 7.1 nM (0.4 and 126 nM), 45.7 nM (14.1 and 149 nM), 28.6 nM (40.5 and 180 nM), 19.7 nM (2.8 and 139 nM) and 26.2 nM (2.1 and 332 nM), respectively, in the presence of 1nM, 10 nM, 31.6 nM, 100 nM or 1 \(\mu\)M CBD. Symbols represent mean values ± SEM.
CBD, 5-HT₁A agonism and nausea

Figure 11
Mean (±SEM) number of gapes elicited by LiCl-paired saccharin solution during the drug-free test trial in Experiments A and B. During conditioning, rats were pretreated with systemic CBD (20.5 mg·kg⁻¹ in Experiment A or 0.05 mg·kg⁻¹ in Experiment B) 15 min prior to saline or 8-OH-DPAT (0.05 mg·kg⁻¹ in Experiment A or 0.005 mg·kg⁻¹ in Experiment B). Thirty minutes later, all rats were conditioned with 0.1% saccharin, followed immediately by LiCl. *P < 0.05., significant difference.

LiCl-induced conditioned gaping in rats. Also, this hypothesis is strengthened further by our finding that the concentration–response curve of CBD for the production of its in vitro effect on [³⁵S]GTPγS binding is bell-shaped, consistent with the 5-HT₁₅-mediated bell-shaped dose–response curves of its effects on emesis (Kwiatkowska et al., 2004), nausea-like-behaviour (Rock et al., 2008), ischaemic injury (Mishima et al., 2005), anxiety (Campos and Guimaraes, 2008) and depression (Zanelati et al., 2010).

Our finding that the concentration of CBD (100 nM) that potentiated 8-OH-DPAT in the [³⁵S]GTPγS binding assay performed with rat brainstem membranes did not significantly alter the rate at which [³⁵H]8-OH-DPAT dissociates from specific binding sites in these membranes does not support the hypothesis that 100 nM CBD potentiates 8-OH-DPAT-induced activation of 5-HT₁₅ receptors in an allosteric manner. However, this hypothesis cannot yet be entirely excluded since it is also possible that the action of an agonist at its receptor could be enhanced by compounds that act on an allosteric site to increase the rate at which the agonist binds to its receptor and/or the intensity of receptor signalling that is induced by such binding (Christopoulos and Kenakin, 2002). That CBD might act in this way to potentiate 5-HT₁₅ receptor activation by 8-OH-DPAT, or indeed by 5-HT, merits further investigation. It will also be important to establish whether CBD produces such potentiation by directly targeting 5-HT₁₅ receptors/allosteric sites or by acting on a different target which then somehow augments 5-HT₁₅ receptor activation by 8-OH-DPAT through an indirect mechanism. There is, therefore, a need for further experiments directed at investigating whether CBD can potentiate 8-OH-DPAT in a cell line that expresses only 5-HT₁₅ receptors.

The anti-emetic potential of CBD not only depends upon its dose, but also upon the nature of the inducing stimulus. In Experiment 3, CBD suppressed vomiting produced by 20 mg·kg⁻¹ cisplatin, but the suppression of vomiting was surmounted by the greater emetic efficiency of the higher dose of 40 mg·kg⁻¹ of cisplatin, suggesting that CBD may not be as effective in reducing nausea produced by highly emetogenic therapies. Furthermore, CBD does not appear to attenuate vomiting produced by activation of the vestibular system by motion (Cluny et al., 2008). This inconsistency may be due to differing neuronal pathways involved in the induction of emesis by these emetogenic stimuli, with the vagal (cisplatin) and blood-borne (LiCl and nicotine) activation of the area postrema (Leslie and Reynolds, 1992) which is not essential to the development of motion sickness.

Interestingly, Yang et al. (2010) have reported that CBD acts as an allosteric inhibitor of 5-HT₁₅ receptor-mediated currents in Xenopus laevis oocytes. Since 5-HT₁₅ antagonists are highly effective anti-emetic/anti-nausea agents (Limebeer and Parker, 2003; Kwiatkowska et al., 2004), it is also likely that the allosteric inhibition of the 5-HT₁₅ receptor may be important in the potential of CBD to regulate nausea and vomiting.

It is not clear which forebrain regions are critical for the effects of CBD on conditioned gaping reactions, but a likely candidate is the insular cortex; the site of convergence of gustatory and interoceptive information (Cechetto and Saper, 1987). Indeed, ablation of the rat insular cortex prevents the establishment of LiCl-induced gaping (Kiefer and Orr, 1992), unlike lesions of the basolateral or central amygdala (Rana and Parker, 2008). Electrical stimulation of the insular cortex produces vomiting in cats (Kaada, 1951) and humans (Catenon et al., 2008), as well as a sensation of nausea in humans (Penfield and Faulk, 1955). Reversible lesions (lidocaine) of the rat insular cortex interfere with the unconditioned behaviour of lying on belly (see Parker, 1984) produced by LiCl (Contreras et al., 2007). In order to determine the role of 5-HT availability in the insular cortex on nausea, future studies will examine the potential of 5,7-DHT lesions of the insular cortex to prevent conditioned gaping reactions in rats.
Acknowledgments

The authors would like to thank Katharine Tuerke and Martin Sticht for assistance with the experiments and Linda Grocock for maintaining the shrew colony. The research reported here was supported by a grant from the Natural Sciences and Engineering Research Council to LAP, a scholarship from NSERC to ER, funding from the National Institute of Drug Abuse (US) to RM and RGP (DA-03672 and DA-09789) and funding from GW Pharmaceuticals to DB, MGC, SAG and RGP.

Conflicts of interest

None.

References


Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108.


